EICHORCondition: Active Systemic Lupus Erythematosus · Sponsor: InventisBio Co., Ltd
Interested? Contact the study team ↓
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.
This description comes directly from the study's public registry record.
Hang Ren, Master · 86+15900699091 · hang.ren@inventisbio.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * The patient voluntarily participates in this study after full informed consent. * The age is 18 years ≤ age ≤ 70 years, regardless of gender. * Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening. * SLEDAI-2K total score ≥ 8. * On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period. Exclusion Criteria: * History of infection as defined in the protocol. * Any of the medical diseases or disorders listed in the protocol. * Significant, uncontrolled or unstable disease in any organ.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Linfen Central Hospital | Linfen, Jiangxi, China | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07311200